Banco Bilbao Vizcaya Argentaria S.A. Boosts Stock Position in Biogen Inc. $BIIB

Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Biogen Inc. (NASDAQ:BIIB) by 6.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 146,951 shares of the biotechnology company’s stock after acquiring an additional 8,297 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A. owned 0.10% of Biogen worth $25,863,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. WPG Advisers LLC raised its position in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the last quarter. First Horizon Corp bought a new position in shares of Biogen in the fourth quarter worth approximately $30,000. Root Financial Partners LLC grew its holdings in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. GoalVest Advisory LLC purchased a new stake in shares of Biogen during the fourth quarter valued at approximately $35,000. Finally, Accredited Wealth Management LLC increased its position in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on BIIB shares. Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. JPMorgan Chase & Co. upped their price target on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Sanford C. Bernstein reduced their price objective on Biogen from $201.00 to $200.00 in a report on Thursday, April 30th. Rothschild & Co Redburn upped their target price on shares of Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Finally, UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and raised their price target for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and an average price target of $216.70.

Biogen Stock Performance

Shares of BIIB opened at $198.67 on Thursday. The firm has a market capitalization of $29.33 billion, a P/E ratio of 21.32 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen Inc. has a one year low of $121.05 and a one year high of $205.97. The business has a fifty day moving average of $190.05 and a 200 day moving average of $184.70.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, sell-side analysts anticipate that Biogen Inc. will post 13.89 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.